We reported that orally-induced higher levels of TMAO in the peripheral blood aggravated behavioral disorders, reduced the level of neurotransmitter 5-HT, and promoted the metabolism of the neurotransmitters DA and 5-HT in the PD mice. This evidence concerns the gene HTR5A and Parkinson disease.